stockrowNeogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
Follow NEOG
Alert me
Neogen Corporation (NEOG) Return on equity
Neogen Corporation's return on equity over the twelve months to 31 August 2026 was −2.67%, down 2.3 percentage points from fiscal 2026 (−0.38%). Over the past ten years it has ranged from −41.9% (fiscal 2025) to 12.2% (fiscal 2018); the current reading is higher than 25% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | −0.38% | 41.50 |
| FY2025 | −41.9% | (41.58) |
| FY2024 | −0.30% | 0.84 |
| FY2023 | −1.14% | (6.73) |
| FY2022 | 5.59% | (2.19) |
| FY2021 | 7.78% | (0.95) |
| FY2020 | 8.73% | (1.32) |
| FY2019 | 10.1% | (2.19) |
| FY2018 | 12.2% | 2.24 |
| FY2017 | 10.0% | 0.32 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| TMDX TransMedics Group, Inc. compare | 31.9% |
| INSP Inspire Medical Systems, Inc. compare | 13.5% |
| ITGR Integer Holdings Corporation compare | 5.97% |
| UFPT UFP Technologies, Inc. compare | 0.00% |
| NEOG Neogen Corporation | −2.67% |
| AXGN AxoGen, Inc. compare | −10.4% |
| BFLY Butterfly Network, Inc. compare | −27.7% |
| ALMR Alamar Biosciences, Inc. compare | −64.5% |
| ESTA Establishment Labs Holdings Inc. compare | −175.3% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on NEOG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement